Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study

Cesare Gridelli, Andrea Ardizzoni, Sandro Barni, Lucio Crinò, Alberto Caprioli, Elena Piazza, Vito Lorusso, Santi Barbera, Nicoletta Zilembo, Vittorio Gebbia, Vincenzo Adamo, Riccardo Pela, Maurizio Marangolo, Raffaella Morena, Gianfranco Filippelli, Calogero Buscarino, Oscar Alabiso, Paolo Maione, Paola Venturino, Filippo De Marinis

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the majority of people diagnosed with NSCLC have locally advanced or metastatic disease. Treatment algorithms have rapidly changed in the last 10 years because of the introduction of new chemotherapeutic and targeted agents in clinical practice. SUN is a 1-year longitudinal observational multicenter study that has consecutively enrolled patients affected by stage IIIB or IV NSCLC with the aim to describe the pattern of care and evolving approaches in the treatment of advanced NSCLC. 987 consecutive NSCLC patients were enrolled between January 2007 and March 2008 at the 74 participating centers throughout Italy and a 12-month follow-up was performed. Cyto-histological diagnosis was performed mainly by broncoscopy with only 24% by CT-scan guided fine-needle aspiration biopsy. 91.4% of the patients received a first-line medical treatment and 8.6% supportive care only. Median age of patients receiving first-line treatment was 66 years. First-line chemotherapy consisted of a single agent in 20% of patients and combination chemotherapy in 80%. The most frequently used chemotherapy regimens were cisplatin plus gemcitabine and carboplatin plus gemcitabine. Median survival of patients receiving first-line chemotherapy was 9.1 months. 32% percent of patients received a second-line treatment that consisted of chemotherapy in 71% of cases and erlotinib in 29%. Overall third-line treatment was given to 7.3% of patients. These results showed a pattern of care for advanced NSCLC that reflects the current clinical practice in Italy at the study time with a high adherence to the International guidelines by the Italian Oncologists.

Original languageEnglish
Pages (from-to)462-468
Number of pages7
JournalLung Cancer
Volume74
Issue number3
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Advanced NSCLC
  • Chemotherapy
  • Docetaxel
  • Erlotinib
  • Observational study
  • Pemetrexed
  • Platin-based chemotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study'. Together they form a unique fingerprint.

Cite this